Limits...
Potential role of S-adenosylmethionine in osteosarcoma development.

Shi H, Mu WD, Zhang B, Meng T, Zhang ST, Zhou DS - Onco Targets Ther (2016)

Bottom Line: The major cause of metastatic osteosarcoma is hypomethylation of numerous genes that undergo overexpression to enable the progression of the disease.In the present study, S-adenosylmethionine (SAM), a predominant methyl donor, was administered to find out its effects on osteosarcoma progression.At the molecular level, the successful inhibition of primary osteosarcoma was found to be associated with a lower expression of Sox2, a protein highly expressed in osteosarcoma stem cells, along with an upregulated expression of TCTP.

View Article: PubMed Central - PubMed

Affiliation: Department of Traumatic Orthopaedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan; Department of Bone and Joint Surgery.

ABSTRACT
The metastatic form of osteosarcoma is a life threatening one since it metastasizes to the lungs. The major cause of metastatic osteosarcoma is hypomethylation of numerous genes that undergo overexpression to enable the progression of the disease. In the present study, S-adenosylmethionine (SAM), a predominant methyl donor, was administered to find out its effects on osteosarcoma progression. As evidence of tumor suppression, the SAM-treated mouse tissue was analyzed histologically, which exemplifies the control that SAM has over abnormal cell proliferation, especially on primary osteosarcoma, but it lacks positive effects on metastatic osteosarcoma. At the molecular level, the successful inhibition of primary osteosarcoma was found to be associated with a lower expression of Sox2, a protein highly expressed in osteosarcoma stem cells, along with an upregulated expression of TCTP. The data suggest that the administration of SAM has a positive role in treating primary osteosarcoma, but it has no role in suppressing metastatic osteosarcoma. The decreased expression of Sox2 together with upregulation of TCTP following SAM administration indicates that SAM has a control over primary osteosarcoma.

No MeSH data available.


Related in: MedlinePlus

Analysis of TCTP expression in normal and osteosarcoma tissues.Notes: (A) TCTP expression in normal bone tissue of a mouse. (B) TCTP expression in primary osteosarcoma tissue. (C) TCTP expression in metastatic osteosarcoma tissue. (D) Increased TCTP expression in SAM-treated primary osteosarcoma tissue. (E) TCTP expression in SAM-treated metastatic osteosarcoma tissue. Scale bar: 100 µm.Abbreviation: SAM, S-adenosylmethionine.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4920229&req=5

f3-ott-9-3653: Analysis of TCTP expression in normal and osteosarcoma tissues.Notes: (A) TCTP expression in normal bone tissue of a mouse. (B) TCTP expression in primary osteosarcoma tissue. (C) TCTP expression in metastatic osteosarcoma tissue. (D) Increased TCTP expression in SAM-treated primary osteosarcoma tissue. (E) TCTP expression in SAM-treated metastatic osteosarcoma tissue. Scale bar: 100 µm.Abbreviation: SAM, S-adenosylmethionine.

Mentions: To understand the osteosarcoma progression and to crosscheck the results further, the expression pattern of TCTP was studied using immunohistochemistry. The control bone tissue had limited TCTP protein expression (Figure 3A), but upon osteosarcoma development, especially in the primary stages of osteosarcoma, there was an increased TCTP protein expression as shown in Figure 3B. But the advanced metastatic osteosarcoma showed only a restricted expression of TCTP with very mild signals (Figure 3C). After SAM treatment, interestingly, the primary osteosarcoma tissue showed an elevated expression of TCTP, which implies the fight back of cells to prevent osteosarcoma (Figure 3D), but in the case of metastatic osteosarcoma, the TCTP expression showed negative changes that resulted in the development of metastatic form.


Potential role of S-adenosylmethionine in osteosarcoma development.

Shi H, Mu WD, Zhang B, Meng T, Zhang ST, Zhou DS - Onco Targets Ther (2016)

Analysis of TCTP expression in normal and osteosarcoma tissues.Notes: (A) TCTP expression in normal bone tissue of a mouse. (B) TCTP expression in primary osteosarcoma tissue. (C) TCTP expression in metastatic osteosarcoma tissue. (D) Increased TCTP expression in SAM-treated primary osteosarcoma tissue. (E) TCTP expression in SAM-treated metastatic osteosarcoma tissue. Scale bar: 100 µm.Abbreviation: SAM, S-adenosylmethionine.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4920229&req=5

f3-ott-9-3653: Analysis of TCTP expression in normal and osteosarcoma tissues.Notes: (A) TCTP expression in normal bone tissue of a mouse. (B) TCTP expression in primary osteosarcoma tissue. (C) TCTP expression in metastatic osteosarcoma tissue. (D) Increased TCTP expression in SAM-treated primary osteosarcoma tissue. (E) TCTP expression in SAM-treated metastatic osteosarcoma tissue. Scale bar: 100 µm.Abbreviation: SAM, S-adenosylmethionine.
Mentions: To understand the osteosarcoma progression and to crosscheck the results further, the expression pattern of TCTP was studied using immunohistochemistry. The control bone tissue had limited TCTP protein expression (Figure 3A), but upon osteosarcoma development, especially in the primary stages of osteosarcoma, there was an increased TCTP protein expression as shown in Figure 3B. But the advanced metastatic osteosarcoma showed only a restricted expression of TCTP with very mild signals (Figure 3C). After SAM treatment, interestingly, the primary osteosarcoma tissue showed an elevated expression of TCTP, which implies the fight back of cells to prevent osteosarcoma (Figure 3D), but in the case of metastatic osteosarcoma, the TCTP expression showed negative changes that resulted in the development of metastatic form.

Bottom Line: The major cause of metastatic osteosarcoma is hypomethylation of numerous genes that undergo overexpression to enable the progression of the disease.In the present study, S-adenosylmethionine (SAM), a predominant methyl donor, was administered to find out its effects on osteosarcoma progression.At the molecular level, the successful inhibition of primary osteosarcoma was found to be associated with a lower expression of Sox2, a protein highly expressed in osteosarcoma stem cells, along with an upregulated expression of TCTP.

View Article: PubMed Central - PubMed

Affiliation: Department of Traumatic Orthopaedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan; Department of Bone and Joint Surgery.

ABSTRACT
The metastatic form of osteosarcoma is a life threatening one since it metastasizes to the lungs. The major cause of metastatic osteosarcoma is hypomethylation of numerous genes that undergo overexpression to enable the progression of the disease. In the present study, S-adenosylmethionine (SAM), a predominant methyl donor, was administered to find out its effects on osteosarcoma progression. As evidence of tumor suppression, the SAM-treated mouse tissue was analyzed histologically, which exemplifies the control that SAM has over abnormal cell proliferation, especially on primary osteosarcoma, but it lacks positive effects on metastatic osteosarcoma. At the molecular level, the successful inhibition of primary osteosarcoma was found to be associated with a lower expression of Sox2, a protein highly expressed in osteosarcoma stem cells, along with an upregulated expression of TCTP. The data suggest that the administration of SAM has a positive role in treating primary osteosarcoma, but it has no role in suppressing metastatic osteosarcoma. The decreased expression of Sox2 together with upregulation of TCTP following SAM administration indicates that SAM has a control over primary osteosarcoma.

No MeSH data available.


Related in: MedlinePlus